# Estrid V HÃ¸gdall

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 179 papers | 8,934 citations | 50276 46 h-index | 49909 87 g-index |
| 179 all docs | 179 docs citations | 179 times ranked | 16149 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Genetic and Functional Drivers of Diffuse Large BâCell Lymphoma. Cell, 2017, 171, 481-494.e15. | 28.9 | 804 |
| 2 | Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 382. | 7.4 | 546 |
| 3 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384. | 21.4 | 493 |
| 4 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691. | 21.4 | 356 |
| 5 | Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncology, The, 2013, 14, 853-862. | 10.7 | 335 |
| 6 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370. | 21.4 | 326 |
| 7 | Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. Journal of Clinical Oncology, 2015, 33, 2901-2907. | 1.6 | 266 |
| 8 | MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer â€" A multicenter prospective comparative study. Gynecologic Oncology, 2013, 128, 300-308. | 1.4 | 183 |
| 9 | The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirusâ€"Positive, Cytologically Normal Women Over a 10-Year Period. Cancer Research, 2006, 66, 10630-10636. | 0.9 | 182 |
| 10 | PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811. | 3.2 | 174 |
| 11 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067. | 9.4 | 157 |
| 12 | Human Papillomavirus Genotyping and p16 Expression As Prognostic Factors for Patients With American Joint Committee on Cancer Stages I to III Carcinoma of the Anal Canal. Journal of Clinical Oncology, 2014, 32, 1812-1817. | 1.6 | 149 |
| 13 | Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International Journal of Epidemiology, 2013, 42, 579-589. | 1.9 | 146 |
| 14 | The diagnostic value of PET/CT for primary ovarian cancerâ€"A prospective study. Gynecologic Oncology, 2007, 105, 145-149. | 1.4 | 145 |
| 15 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628. | 12.8 | 144 |
| 16 | Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 652-657. | 7.0 | 138 |
| 17 | Sample Handling for Mass Spectrometric Proteomic Investigations of Human Sera. Analytical Chemistry, 2005, 77, 5114-5123. | 6.5 | 129 |
| 18 | Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014. European Journal of Cancer, 2017, 70, 75-82. | 2.8 | 115 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630. | 1.9 | 111 |
| 20 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627. | 12.8 | 98 |
| 21 | Different Risk Factor Profiles for Mucinous and Nonmucinous Ovarian Cancer: Results from the Danish MALOVA Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1160-1166. | 2.5 | 95 |
| 22 | Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer. Archives of Internal Medicine, 2004, 164, 2253. | 3.8 | 94 |
| 23 | BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. Clinical Cancer Research, 2008, 14, 3761-3767. | 7.0 | 92 |
| 24 | RNA profiles reveal signatures of future health and disease in pregnancy. Nature, 2022, 601, 422-427. | 27.8 | 90 |
| 25 | Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 caseâ€“control studies. Cancer Causes and Control, 2013, 24, 989-1004. | 1.8 | 84 |
| 26 | BRAF inhibition improves tumor recognition by the immune system. OncoImmunology, 2012, 1, 1476-1483. | 4.6 | 82 |
| 27 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675. | 12.8 | 78 |
| 28 | High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. Apmis, 2011, 119, 663-673. | 2.0 | 74 |
| 29 | Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. British Journal of Cancer, 2016, 114, 134-137. | 6.4 | 73 |
| 30 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895. | 1.9 | 71 |
| 31 | miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan. PLoS ONE, 2014, 9, e99886. | 2.5 | 68 |
| 32 | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964. | 2.9 | 68 |
| 33 | HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2285-2295. | 2.5 | 65 |
| 34 | MicroRNA Biomarkers in IBDâ€”Differential Diagnosis and Prediction of Colitis-Associated Cancer. International Journal of Molecular Sciences, 2020, 21, 7893. | 4.1 | 64 |
| 35 | Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 847, 30-37. | 2.3 | 63 |
| 36 | Cancer antigen 125 and prognosis. Current Opinion in Obstetrics and Gynecology, 2008, 20, 4-8. | 2.0 | 62 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status. Cellular Oncology (Dordrecht), 2014, 37, 215-227. | 4.4 | 62 |
| 38 | Bacterial Infection as a Likely Cause of Adverse Reactions to Polyacrylamide Hydrogel Fillers in Cosmetic Surgery. Clinical Infectious Diseases, 2013, 56, 1438-1444. | 5.8 | 61 |
| 39 | Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. American Journal of Epidemiology, 2017, 185, 8-20. | 3.4 | 61 |
| 40 | Frequencies and Prognostic Role of KRAS and BRAF Mutations in Patients With Localized Pancreatic and Ampullary Adenocarcinomas. Pancreas, 2012, 41, 759-766. | 1.1 | 60 |
| 41 | <scp>HE</scp>4 and <scp>CA</scp>125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (<scp>ENDOMET</scp>). Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 1313-1322. | 2.8 | 60 |
| 42 | Inflammatory Bowel Disease and Small Bowel Cancer Risk,ÂClinical Characteristics, and Histopathology: AÂPopulation-Based Study. Clinical Gastroenterology and Hepatology, 2017, 15, 1900-1907.e2. | 4.4 | 59 |
| 43 | The prevalence of <scp>EGFR</scp> mutations in nonâ€small cell lung cancer in an unselected Caucasian population. Apmis, 2015, 123, 108-115. | 2.0 | 55 |
| 44 | Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. International Journal of Cancer, 2011, 128, 2063-2074. | 5.1 | 54 |
| 45 | Smoking and Overweight: Negative Prognostic Factors in Stage III Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 798-803. | 2.5 | 50 |
| 46 | Influence of 2-(18F) Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography on Recurrent Ovarian Cancer Diagnosis and on Selection of Patients for Secondary Cytoreductive Surgery. International Journal of Gynecological Cancer, 2009, 19, 600-604. | 2.5 | 49 |
| 47 | The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750. | 7.0 | 47 |
| 48 | SUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patients. Gynecologic Oncology, 2013, 129, 298-303. | 1.4 | 47 |
| 49 | Human Papillomavirus in Head and Neck Squamous Cell Carcinoma of Unknown Primary Is a Common Event and a Strong Predictor of Survival. PLoS ONE, 2014, 9, e110456. | 2.5 | 44 |
| 50 | Association between Common Germline Genetic Variation in 94 Candidate Genes or Regions and Risks of Invasive Epithelial Ovarian Cancer. PLoS ONE, 2009, 4, e5983. | 2.5 | 38 |
| 51 | Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. PLoS ONE, 2018, 13, e0207319. | 2.5 | 35 |
| 52 | Clinical Implications of Intestinal Stem Cell Markers in Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 63-71. | 2.3 | 34 |
| 53 | Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bclâ€2, coxâ€2, actin, calponin, D2â€40 (podoplanin), mdmâ€2, CD117 (câ€kit), and YKLâ€40. Apmis, 2009, 117, 518-525. | 2.2 | 33 |
| 54 | Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer. Acta OncolÃ³gica, 2011, 50, 415-419. | 1.8 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276. | 7.0 | 33 |
| 56 | Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). Gynecologic Oncology, 2016, 142, 50-53. | 1.4 | 33 |
| 57 | Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles. Modern Pathology, 2018, 31, 1211-1225. | 5.5 | 33 |
| 58 | Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors. Cancer Causes and Control, 2013, 24, 1459-1464. | 1.8 | 32 |
| 59 | Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1638-1648. | 2.5 | 31 |
| 60 | The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecologic Oncology, 2015, 136, 205-211. | 1.4 | 30 |
| 61 | Current status on micro<scp>RNA</scp>s as biomarkers for ovarian cancer. Apmis, 2016, 124, 337-355. | 2.0 | 30 |
| 62 | Molecular signatures of thyroid follicular neoplasia. Endocrine-Related Cancer, 2010, 17, 691-708. | 3.1 | 28 |
| 63 | Positron Emission Tomography/Computed Tomography Predictors of Overall Survival in Stage IIIC/IV Ovarian Cancer. International Journal of Gynecological Cancer, 2012, 22, 1163-1169. | 2.5 | 28 |
| 64 | Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. BMC Cancer, 2013, 13, 28. | 2.6 | 28 |
| 65 | History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes and Control, 2017, 28, 469-486. | 1.8 | 28 |
| 66 | PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma. Oncotarget, 2015, 6, 32266-32278. | 1.8 | 28 |
| 67 | Accuracy of self-reported family history of cancer in a large caseâ€“control study of ovarian cancer. Cancer Causes and Control, 2008, 19, 469-479. | 1.8 | 27 |
| 68 | MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability. BMC Cancer, 2015, 15, 1024. | 2.6 | 27 |
| 69 | Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction. OncoImmunology, 2018, 7, e1412029. | 4.6 | 27 |
| 70 | Early Laboratory Diagnosis of COVID-19 by Antigen Detection in Blood Samples of the SARS-CoV-2 Nucleocapsid Protein. Journal of Clinical Microbiology, 2021, 59, e0100121. | 3.9 | 27 |
| 71 | Proteomic biomarkers for overall and progressionâ€free survival in ovarian cancer patients. Proteomics - Clinical Applications, 2010, 4, 940-952. | 1.6 | 26 |
| 72 | Risk factors for brain metastases in patients with metastatic colorectal cancer. Acta OncolÃ³gica, 2017, 56, 639-645. | 1.8 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA. Cancer Cytopathology, 2018, 126, 275-281. | 2.4 | 26 |
| 74 | MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 329-340. | 2.8 | 26 |
| 75 | Methylation and ovarian cancer: Can DNA methylation be of diagnostic use? (Review). Molecular and Clinical Oncology, 2019, 10, 323-330. | 1.0 | 26 |
| 76 | Use of dairy products, lactose, and calcium and risk of ovarian cancer â€“ Results from a Danish case-control study. Acta OncolÃ³gica, 2012, 51, 454-464. | 1.8 | 25 |
| 77 | Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal of Cancer, 2017, 140, 2422-2435. | 5.1 | 25 |
| 78 | Genetic Variation in TYMS in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1822-1830. | 2.5 | 24 |
| 79 | miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer. Frontiers in Oncology, 2014, 4, 207. | 2.8 | 24 |
| 80 | Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: Results from a Danish case-control study. Acta OncolÃ³gica, 2015, 54, 1144-1151. | 1.8 | 24 |
| 81 | SOX9 expression predicts relapse of stage II colon cancer patients. Human Pathology, 2016, 52, 38-46. | 2.0 | 24 |
| 82 | Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. Acta OncolÃ³gica, 2018, 57, 1057-1062. | 1.8 | 24 |
| 83 | Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass. PLoS ONE, 2019, 14, e0225249. | 2.5 | 24 |
| 84 | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497. | 3.8 | 23 |
| 85 | Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535. | 6.4 | 23 |
| 86 | Identification of bacteria using two degenerate 16S rDNA sequencing primers. Microbiological Research, 1999, 154, 23-26. | 5.3 | 22 |
| 87 | Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Proteomics - Clinical Applications, 2010, 4, 304-314. | 1.6 | 22 |
| 88 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320. | 3.0 | 22 |
| 89 | Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. Apmis, 2006, 114, 359-363. | 2.0 | 21 |
| 90 | Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e20703. | 2.5 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | <scp>KRAS</scp> and <scp>BRAF</scp> mutations in anal carcinoma. Apmis, 2015, 123, 53-59. | 2.0 | 20 |
| 92 | Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histologyâ€"A Comparative Study. International Journal of Gynecological Cancer, 2016, 26, 82-90. | 2.5 | 20 |
| 93 | The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology, 2016, 41, 71-79. | 1.9 | 20 |
| 94 | Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2017, 28, 459-468. | 1.8 | 20 |
| 95 | Use of analgesic drugs and risk of ovarian cancer: results from a Danish caseâ€"control study. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 1094-1102. | 2.8 | 19 |
| 96 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756. | 3.8 | 19 |
| 97 | A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIICâ€"IV ovarian cancerâ€"a part of the Danish prospective pelvic mass study. Tumor Biology, 2016, 37, 12619-12626. | 1.8 | 19 |
| 98 | Oncomineâ„¢ Comprehensive Assay v3 vs. Oncomineâ„¢ Comprehensive Assay Plus. Cancers, 2021, 13, 5230. | 3.7 | 19 |
| 99 | Risk of ovarian cancer in women with first-degree relatives with cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2009, 88, 449-456. | 2.8 | 18 |
| 100 | High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer. Modern Pathology, 2014, 27, 1590-1598. | 5.5 | 18 |
| 101 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401. | 1.4 | 18 |
| 102 | A Highly Sensitive Quantitative Real-Time PCR Assay for Determination of Mutant JAK2 Exon 12 Allele Burden. PLoS ONE, 2012, 7, e33100. | 2.5 | 18 |
| 103 | A novel monoclonal antibody to a defined peptide epitope in MUC16. Glycobiology, 2015, 25, 1172-1182. | 2.5 | 17 |
| 104 | Intra-tumor heterogeneity of microRNA-92a, microRNA-375 and microRNA-424 in colorectal cancer. Experimental and Molecular Pathology, 2016, 100, 125-131. | 2.1 | 17 |
| 105 | Demographic, Clinical, and Prognostic Factors of Ovarian Clear Cell Adenocarcinomas According to Endometriosis Status. International Journal of Gynecological Cancer, 2017, 27, 1804-1812. | 2.5 | 17 |
| 106 | Next Generation Sequencing Technology in the Clinic and Its Challenges. Cancers, 2021, 13, 1751. | 3.7 | 17 |
| 107 | Consortium analysis of gene and geneâ€"folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035. | 3.3 | 16 |
| 108 | History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, 2017, 117, 1063-1069. | 6.4 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front. Human Pathology, 2018, 80, 231-238. | 2.0 | 16 |
| 110 | Evidence of No Association Between Human Papillomavirus and Breast Cancer. Frontiers in Oncology, 2018, 8, 209. | 2.8 | 15 |
| 111 | Digital image analysis of pan-cytokeratin stained tumor slides for evaluation of tumor budding in pT1/pT2 colorectal cancer: Results of a feasibility study. Pathology Research and Practice, 2018, 214, 1273-1281. | 2.3 | 15 |
| 112 | The prevalence of EBV and CMV DNA in epithelial ovarian cancer. Infectious Agents and Cancer, 2019, 14, 7. | 2.6 | 15 |
| 113 | Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709. | 1.4 | 15 |
| 114 | Feasibility of Serodiagnosis of Ovarian Cancer by Mass Spectrometry. Analytical Chemistry, 2009, 81, 1907-1913. | 6.5 | 14 |
| 115 | Topoisomeraseâ€1 gene copy aberrations are frequent in patients with breast cancer. International Journal of Cancer, 2015, 137, 2000-2006. | 5.1 | 14 |
| 116 | Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project. Contemporary Clinical Trials Communications, 2017, 8, 167-174. | 1.1 | 14 |
| 117 | Deep sequencing of human papillomavirus positive loco-regionally advanced oropharyngeal squamous cell carcinomas reveals novel mutational signature. BMC Cancer, 2018, 18, 640. | 2.6 | 14 |
| 118 | Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: Identification of mRNAs and microRNAs involved in tumor invasion. Gene, 2013, 517, 72-81. | 2.2 | 13 |
| 119 | Remodeling of the Tumor Microenvironment Predicts Increased Risk of Cancer in Postmenopausal Women: The Prospective Epidemiologic Risk Factor (PERF I) Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1348-1355. | 2.5 | 13 |
| 120 | Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228. | 6.4 | 13 |
| 121 | High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach. Journal of Infectious Diseases, 2019, 220, 1312-1324. | 4.0 | 13 |
| 122 | Circulating Antinuclear Antibodies in Patients with Pelvic Masses Are Associated with Malignancy and Decreased Survival. PLoS ONE, 2012, 7, e30997. | 2.5 | 13 |
| 123 | DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis. Endoscopic Ultrasound, 2020, 9, 37. | 1.5 | 13 |
| 124 | The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome. Prenatal Diagnosis, 2002, 22, 385-387. | 2.3 | 12 |
| 125 | Gene Expression Profiles as Prognostic Markers in Women With Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, 1205-1213. | 2.5 | 12 |
| 126 | Prognostic value of tissue protein expression levels of <scp>MIB</scp>â€1 (Kiâ€67) in Danish ovarian cancer patients. From the â€˜<scp>MALOVA</scp>â€™ ovarian cancer study. Apmis, 2013, 121, 1177-1186. | 2.0 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 2039-2046. | 1.3 | 12 |
| 128 | Investigating intra-tumor heterogeneity and expression gradients of miR-21, miR-92a and miR-200c and their potential of predicting lymph node metastases in early colorectal cancer. Experimental and Molecular Pathology, 2016, 101, 187-196. | 2.1 | 12 |
| 129 | Sample handling for mass spectrometric proteomic investigations of human urine. Proteomics - Clinical Applications, 2008, 2, 1184-1193. | 1.6 | 11 |
| 130 | Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. PLoS ONE, 2017, 12, e0174300. | 2.5 | 11 |
| 131 | Effect of inhibition of CBP-coactivated Î²-catenin-mediated Wnt signalling in uremic rats with vascular calcifications. PLoS ONE, 2018, 13, e0201936. | 2.5 | 11 |
| 132 | Gene expression profile association with poor prognosis in epithelial ovarian cancer patients. Scientific Reports, 2021, 11, 5438. | 3.3 | 11 |
| 133 | <scp>HPV</scp> genotype distribution in older Danish women undergoing surgery due to cervical cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2015, 94, 1262-1268. | 2.8 | 10 |
| 134 | Hyperplastic polyps of the colon and rectum â€“ reclassification, <scp>BRAF</scp> and <scp>KRAS</scp> status in index polyps and subsequent colorectal carcinoma. Apmis, 2015, 123, 298-304. | 2.0 | 10 |
| 135 | HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. Apmis, 2016, 124, 1038-1045. | 2.0 | 10 |
| 136 | Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. Oncology Letters, 2016, 11, 393-398. | 1.8 | 10 |
| 137 | Assessment of Multifactor Geneâ€“Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 780-790. | 2.5 | 10 |
| 138 | History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1470-1473. | 2.5 | 10 |
| 139 | Optimized Biobanking Procedures for Preservation of RNA in Tissue: Comparison of Snap-Freezing and RNAlater-Fixation Methods. Biopreservation and Biobanking, 2019, 17, 562-569. | 1.0 | 10 |
| 140 | Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures. Cancers, 2021, 13, 5242. | 3.7 | 10 |
| 141 | The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients. Cells, 2022, 11, 2170. | 4.1 | 10 |
| 142 | Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. Anticancer Research, 2019, 39, 2475-2482. | 1.1 | 9 |
| 143 | Evaluation of analytical accuracy of HER2 status in patients with breast cancer. Apmis, 2020, 128, 573-582. | 2.0 | 9 |
| 144 | Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. Twin Research and Human Genetics, 2012, 15, 615-623. | 0.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Comparison of FluorescenceIn SituHybridization and ChromogenicIn SituHybridization for Low and High ThroughputHER2Genetic Testing. International Journal of Breast Cancer, 2013, 2013, 1-5. | 1.2 | 8 |
| 146 | Approaches to the detection of ovarian cancer. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, S49-S53. | 1.2 | 7 |
| 147 | Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases. Reproductive Sciences, 2021, 28, 757-765. | 2.5 | 7 |
| 148 | The somatic mode: doing good in targeted cancer therapy. New Genetics and Society, 2021, 40, 178-198. | 1.2 | 7 |
| 149 | DNA Methylation in Ovarian Tumorsâ€"a Comparison Between Fresh Tissue and FFPE Samples. Reproductive Sciences, 2021, 28, 3212-3218. | 2.5 | 7 |
| 150 | Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. Clinica Chimica Acta, 2021, 522, 152-157. | 1.1 | 7 |
| 151 | Serum tetranectin is a significant prognostic marker in ovarian cancer patients. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 190-198. | 2.8 | 6 |
| 152 | Serum <scp>YKL</scp>â€40 and uterine artery Doppler â€“ a prospective cohort study, with focus on preeclampsia and smallâ€forâ€gestationalâ€age. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 817-824. | 2.8 | 6 |
| 153 | Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. Results from the â€˜Malovaâ€™ ovarian cancer study. Apmis, 2015, 123, 401-409. | 2.0 | 6 |
| 154 | Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer. International Journal of Gynecological Cancer, 2020, 30, 1034-1042. | 2.5 | 6 |
| 155 | A Proteomics Panel for Predicting Optimal Primary Cytoreduction in Stage III/IV Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, 1535-1538. | 2.5 | 5 |
| 156 | Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e19642. | 2.5 | 5 |
| 157 | (GT)n Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. PLoS ONE, 2016, 11, e0168210. | 2.5 | 5 |
| 158 | Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer. Oncotarget, 2017, 8, 108213-108222. | 1.8 | 5 |
| 159 | The prognostic value of polycomb group protein Bâ€cellâ€specific moloney murine leukemia virus insertion site 1 in stage <scp>II</scp> colon cancer patients. Apmis, 2016, 124, 541-546. | 2.0 | 4 |
| 160 | Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 507-514. | 2.8 | 4 |
| 161 | MicroRNA characteristics in epithelial ovarian cancer. PLoS ONE, 2021, 16, e0252401. | 2.5 | 4 |
| 162 | Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer. PLoS ONE, 2021, 16, e0255142. | 2.5 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Exome sequencing of 22 genes using tissue from patients with biliary tract cancer. Apmis, 2020, 128, 3-9. | 2.0 | 3 |
| 164 | Targeting the Supply Lines of Cancer â€“ A Possible Strategy for Combating the Disease?. Anticancer Research, 2021, 41, 2737-2744. | 1.1 | 3 |
| 165 | CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancerâ€”A Multicenter Analysis. Cancers, 2022, 14, 1954. | 3.7 | 3 |
| 166 | Diagnostic accuracy of risk of malignancy index in predicting complete tumor removal at primary debulking surgery for ovarian cancer patients. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 721-726. | 2.8 | 2 |
| 167 | The prospect of discovering new biomarkers for ovarian cancer based on current knowledge ofï¿½susceptibility loci and genetic variation (Review). International Journal of Molecular Medicine, 2019, 44, 1599-1608. | 4.0 | 2 |
| 168 | Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma. Gynecologic Oncology, 2022, 164, 543-549. | 1.4 | 2 |
| 169 | Organoids and epithelial ovarian cancer â€˜ a future tool for personalized treatment decisions?. Molecular and Clinical Oncology, 2021, 16, 29. | 1.0 | 2 |
| 170 | Preoperative predictors of inguinal lymph node metastases in vulvar cancer â€“ A nationwide study. Gynecologic Oncology, 2022, 165, 420-427. | 1.4 | 2 |
| 171 | Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients. Gynecologic Oncology, 2010, 117, 446-450. | 1.4 | 1 |
| 172 | Ovarian Clear Cell Carcinoma: From Morphology to Molecular Biology. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 631-636. | 1.2 | 1 |
| 173 | Incidents in Molecular Pathology: Frequency and Causes During Routine Testing. Archives of Pathology and Laboratory Medicine, 2021, 145, 1270-1279. | 2.5 | 1 |
| 174 | Impact of microRNA miR-345 in blood on survival and response in 144 patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan.. Journal of Clinical Oncology, 2012, 30, 451-451. | 1.6 | 1 |
| 175 | Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1028-1031. | 2.5 | 0 |
| 176 | Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma. Experimental Hematology, 2015, 43, 534-536. | 0.4 | 0 |
| 177 | FP375EFFECT OF WNT-INHIBITION ON ESTABLISHED VASCULAR CALCIFICATION IN UREMIC RATS. Nephrology Dialysis Transplantation, 2018, 33, i159-i159. | 0.7 | 0 |
| 178 | The nationwide Danish CancerBiobank: Future possibilies.. Journal of Clinical Oncology, 2014, 32, e22196-e22196. | 1.6 | 0 |
| 179 | Outcome of cetuximab plus irinotecan in relation to RAS and BRAF mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan.. Journal of Clinical Oncology, 2016, 34, e15115-e15115. | 1.6 | 0 |